mRNA-based therapies hold immense potential for treating a plethora of diseases. However, their application to central nervous system (CNS) disorders remains limited due to biological barriers, such as rapid degradation in circulation, restricted brain access, and endosomal entrapment within cells. To address these challenges, we developed a polymeric micelle-based nanocarrier capable of systemically delivering mRNA to the brain. This system employed triphenylphosphonium (TPP) as a cationic moiety to stably complex with mRNA and prolong its blood circulation. TPP was introduced into a PEG-polyaspartamide derivative bearing diethylenetriamines, whose pH-responsive ionizable amines facilitated endosomal escape. For brain targeting, antibody fragments against transferrin receptor 1 were conjugated to the PEG shell at a controlled density via click chemistry. This rational, multifaceted design enabled robust in situ protein production in the brain following systemic administration, achieving around a 10-fold increase compared to our initial formulation, while exerting lower impact on off-target expression in other organs. Our system offers a promising platform for systemic mRNA delivery to the brain, opening new avenues for treating CNS disorders.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jumpei Norimatsu
Innovation Center of NanoMedicine
Hayato Laurence Mizuno
Tokyo Institute of Technology
Yuki Mochida
Tokyo Medical and Dental University
Molecular Pharmaceutics
The University of Tokyo
Tokyo Institute of Technology
Innovation Center of NanoMedicine
Building similarity graph...
Analyzing shared references across papers
Loading...
Norimatsu et al. (Mon,) studied this question.
synapsesocial.com/papers/69df2cf7e4eeef8a2a6b2031 — DOI: https://doi.org/10.1021/acs.molpharmaceut.5c01925
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: